Kaitlyn C. Chapin

Kaitlyn C. Chapin

Auto-generated profile, based on publicly available information

Kaitlyn C. Chapin

Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in Transplant Infectious Disease
Verified
Journal Article
Open access
ATAnil J. Trindade
Anil J. Trindade
KCKaitlyn C. Chapin
Kaitlyn C. Chapin
WGWhitney D. Gannon
Whitney D. Gannon
HHHaley Hoy
Haley Hoy
CDCaitlin T. Demarest
Caitlin T. Demarest
CSCiara M. Shaver
Ciara M. Shaver
Background: Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in lung transplant recipients remain limited.Methods: We performed a single‐center, observational study of outcomes in lung transplant recipients diagnosed with SARS‐CoV‐2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.Results: In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre‐Delta, 20 Delta, and 56 Omicron‐era). Twenty‐five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID‐19 did not alter change in forced expiratory volume in 1 s (FEV1) or forced vital capacity (FVC) over time compared to the preceding 6 months. The pre‐COVID FEV1change was −0.05 ml/day (IQR −0.50 to 0.60) compared to −0.20 ml/day (IQR −1.40 to 0.70) post‐COVID (p = .16). The pre‐COVID change in FVC was 0.20 ml/day (IQR −0.60 to 0.70) compared to 0.05 ml/day (IQR −1.00 to 1.10) post‐COVID (p = .76). Although the cohort overall had stable lung function, 33 patients (39%) developed ALAD or accelerated chronic lung allograft dysfunction (FEV1decline >10% from pre‐COVID baseline). Nine patients (35%) with ALAD recovered lung function. Within 3 months of acute COVID infection, 18 patients (17%) developed secondary infections, the majority being bacterial pneumonia. Finally, vaccination with at least two doses of mRNA vaccine was not associated with improved outcomes.Conclusions: This study describes the natural history of SARS‐CoV‐2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS‐CoV‐2 is not associated with worsening lung function. image

13 January 2025 in Clinical Transplantation
Verified
Journal Article
Open access
ADAlexander G. Dragnich
Alexander G. Dragnich
KCKaitlyn C. Chapin
Kaitlyn C. Chapin
KXKe Xu
Ke Xu
JLJinyuan Liu
Jinyuan Liu
LLLoren Lipworth
Loren Lipworth
ATAnil J. Trindade
Anil J. Trindade
The importance of mental toughness on lung transplant outcomes is unknown. We performed a pilot study to assess whether pretransplant grit and resilience are associated with short‐term posttransplant outcomes. We enrolled 31 lung transplant candidates, of whom 7 (26%) had greater mental toughness, defined as the upper tertile for both grit and resilience within our cohort. There were no differences in baseline characteristics between patients with higher and lower mental toughness. Greater mental toughness was associated with a shorter hospital length of stay (LOS) [12 days (interquartile range, IQR 10–12) vs. 17 days (IQR 14–24), p = 0.02] and reduced posttraumatic stress severity [median 0 (IQR 0–2) vs. 6.5 (IQR 4–9), p < 0.01]. On multivariable analyses adjusting for age and Duke Activity Status Index, greater mental toughness was associated with a shorter hospital LOS [beta = −11.96 (95% CI 0.05–23.86), p < 0.05] and reduced PTSD [beta = −10.7 (95% CI −21.6–0.04), p = 0.053]. Lung transplant candidates with greater mental toughness may have improved short‐term outcomes.

12 August 2026 in JHLT Open
Verified
Journal Article
Open access
ATAlexandra H. Toporek
Alexandra H. Toporek
WGWhitney D. Gannon
Whitney D. Gannon
MCMichael P. Croglio
Michael P. Croglio
DMDaniel Motta-Calderon
Daniel Motta-Calderon
ADAlexander G. Dragnich
Alexander G. Dragnich
ATAnil J. Trindade
Anil J. Trindade
The pragmatic aspects of routine lung transplant recipient management are poorly described. We performed an international survey study to characterize management of stable lung transplant recipients who are beyond the initial post-transplant year. We obtained survey responses from 72 distinct lung transplant programs in 15 countries. Stable patients are monitored a median of every 3-months (IQR 3-3.25) in the ambulatory setting. Visits are accompanied by diagnostic laboratory assessments, spirometry, and chest X-ray imaging. Most centers perform between-clinic surveillance every 1-month (IQR 1-1.5) with diagnostic laboratory testing. We identified the frequency of monitoring of donor-specific antibodies [median 6 months (IQR 3-6)], chest computed tomography [median 12 months (IQR 12-12)], and other ancillary testing. A majority of stable patients are managed on a maintenance immunosuppression regimen of tacrolimus (preferred goal trough 8-10 ng/ml), mycophenolate, and prednisone (preferred dose of 5 mg daily). Dose reduction of immunosuppression occurs for cytopenias, recurrent infection, malignancy, and short telomere syndromes at most centers. Methodologies and frequencies for malignancy screening are described. While routine care of lung transplant recipients is heterogeneous, there are potential areas of consensus in practice patterns.